Resverlogix’s Reprieve: ASSURE Results Suggest RVX-208 Works When Given With Crestor
This article was originally published in The Pink Sheet Daily
Executive Summary
While the ASSURE study failed overall, it turns out that a subset taking the HDL-raising drug candidate with the statin Crestor did benefit from treatment; Resverlogix is now planning to develop the combination.
You may also be interested in...
In Another Blow For HDL Therapies, Cerenis’ CER-001 Stumbles In Phase II
Intravenous HDL mimetic candidate CER-001 misses endpoint for regression of plaque in Phase IIb study, but Cerenis indicates it’s still committed to the therapy.
In Another Blow For HDL Therapies, Cerenis’ CER-001 Stumbles In Phase II
Intravenous HDL mimetic candidate CER-001 misses endpoint for regression of plaque in Phase IIb study, but Cerenis indicates it’s still committed to the therapy.
Dalcetrapib Failure Raises Yet More Questions On Value Of Tinkering With HDL Cholesterol
Termination of the development program for dalcetrapib creates more doubt about the class of CETP inhibitors, long viewed with ambivalence. But important differences in how the drug works compared to rivals leaves room for some to hold out hope for CETP inhibition and the HDL hypothesis in general.